82 related articles for article (PubMed ID: 12193102)
1. Role of endothelin-1 in the development of a special type of cardiomyopathy.
Zsáry A; Szücs S; Schneider T; Rosta A; Sármán P; Fenyvesi T; Karádi I
Clin Sci (Lond); 2002 Aug; 103 Suppl 48():272S-275S. PubMed ID: 12193102
[TBL] [Abstract][Full Text] [Related]
2. [Effect of high-dose chemotherapy with subsequent transplantation of blood-forming cells on left ventricle function in patients with malignant lymphomas treated with doxorubicin in primary chemotherapy].
Elbl L; Vásová I; Krejcí M; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Mayer J; Vorlícek J
Vnitr Lek; 2006 Mar; 52(3):221-31. PubMed ID: 16722153
[TBL] [Abstract][Full Text] [Related]
3. Endothelin-1 and cardiac function in anthracycline-treated patients: a 1-year follow-up.
Zsáry A; Szücs S; Keltai K; Pásztor E; Schneider T; Rosta A; Sármán P; Jánoskuti L; Fenyvesi T; Karádi I
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S372-5. PubMed ID: 15838323
[TBL] [Abstract][Full Text] [Related]
4. Endothelins: a possible mechanism of cytostatics-induced cardiomyopathy.
Zsáry A; Szûcs S; Keltai K; Schneider T; Rosta A; Sármán P; Fenyvesi T; Karádi I
Leuk Lymphoma; 2004 Feb; 45(2):351-5. PubMed ID: 15101723
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients.
Nousiainen T; Vanninen E; Jantunen E; Remes J; Ritanen E; Vuolteenaho O; Hartikainen J
Clin Sci (Lond); 2001 Dec; 101(6):601-7. PubMed ID: 11724646
[TBL] [Abstract][Full Text] [Related]
6. [Late cardiotoxicity in patients with malignant lymphoma treated with doxorubicin chemotherapy].
Elbl L; Vásová I; Navrátil M; Tomásková I; Jedlicka F; Chaloupka V; Vorlícek J
Vnitr Lek; 2006 Apr; 52(4):328-38. PubMed ID: 16755989
[TBL] [Abstract][Full Text] [Related]
7. Cardiopulmonary response to exercise in patients with different degrees of lung toxicity after radio-chemotherapy for Hodgkin's disease.
Villani F; Busia A; Villani M; Laffranchi A; Viviani S; Bonfante V
Anticancer Res; 2009 Feb; 29(2):777-83. PubMed ID: 19331235
[TBL] [Abstract][Full Text] [Related]
8. Cardiac function and cardiopulmonary performance in patients after treatment for non-Hodgkin's lymphoma.
Elbl L; Vasova I; Tomaskova I; Jedlicka F; Navratil M; Pospisil Z; Vorlicek J
Neoplasma; 2006; 53(2):174-81. PubMed ID: 16575475
[TBL] [Abstract][Full Text] [Related]
9. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group.
Engert A; Schiller P; Josting A; Herrmann R; Koch P; Sieber M; Boissevain F; De Wit M; Mezger J; Duhmke E; Willich N; Muller RP; Schmidt BF; Renner H; Muller-Hermelink HK; Pfistner B; Wolf J; Hasenclever D; Loffler M; Diehl V;
J Clin Oncol; 2003 Oct; 21(19):3601-8. PubMed ID: 12913100
[TBL] [Abstract][Full Text] [Related]
10. Left ventricular function assessed by two-dimensional speckle tracking echocardiography in long-term survivors of Hodgkin's lymphoma treated by mediastinal radiotherapy with or without anthracycline therapy.
Tsai HR; Gjesdal O; Wethal T; Haugaa KH; Fosså A; Fosså SD; Edvardsen T
Am J Cardiol; 2011 Feb; 107(3):472-7. PubMed ID: 21257017
[TBL] [Abstract][Full Text] [Related]
11. [Changes in left ventricular function during chemotherapy with doxorubicin].
Elbl L; Chaloupka V; Vásová I; Kiss I; Jancík J; Vorlícek J; Navrátil M
Vnitr Lek; 1999 Jul; 45(7):395-402. PubMed ID: 11045157
[TBL] [Abstract][Full Text] [Related]
12. An elevated serum beta-2-microglobulin level is an adverse prognostic factor for overall survival in patients with early-stage Hodgkin disease.
Chronowski GM; Wilder RB; Tucker SL; Ha CS; Sarris AH; Hagemeister FB; Barista I; Hess MA; Cabanillas F; Cox JD
Cancer; 2002 Dec; 95(12):2534-8. PubMed ID: 12467067
[TBL] [Abstract][Full Text] [Related]
13. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
14. Low acute hematological toxicity during chemotherapy predicts reduced disease control in advanced Hodgkin's disease.
Brosteanu O; Hasenclever D; Loeffler M; Diehl V;
Ann Hematol; 2004 Mar; 83(3):176-82. PubMed ID: 15064867
[TBL] [Abstract][Full Text] [Related]
15. [Hematologic tumors].
Ogawa M
Gan To Kagaku Ryoho; 2003 Oct; 30(10):1416-21. PubMed ID: 14584273
[TBL] [Abstract][Full Text] [Related]
16. ABVD versus modified stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: final results of a multicenter randomized trial by the Intergruppo Italiano Linfomi.
Gobbi PG; Levis A; Chisesi T; Broglia C; Vitolo U; Stelitano C; Pavone V; Cavanna L; Santini G; Merli F; Liberati M; Baldini L; Deliliers GL; Angelucci E; Bordonaro R; Federico M;
J Clin Oncol; 2005 Dec; 23(36):9198-207. PubMed ID: 16172458
[TBL] [Abstract][Full Text] [Related]
17. Biophysical analysis of the acute toxicity of radiotherapy in Hodgkin's lymphoma--a comparison between extended field and involved field radiotherapy based on the data of the German Hodgkin Study Group.
Eich HT; Haverkamp U; Engert A; Kocher M; Skripnitchenko R; Brillant C; Sehlen S; Dühmke E; Diehl V; Müller RP
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):860-5. PubMed ID: 15925455
[TBL] [Abstract][Full Text] [Related]
18. Treatment of patients with advanced or bulky Hodgkin disease with a 12-week doxorubicin, bleomycin, vinblastine, and dacarbazine-like chemotherapy regimen followed by extended-field, full-dose radiotherapy: long-term results of the Groupe Ouest et Est des Leucémies et Autres Maladies de Sang H90-A/B Multicenter Randomized Trial.
Djeridane M; Oudard S; Escoffre-Barbe M; Lacotte-Thierry L; Desablens B; Briére J; Dib M; Cassasus P; Ghandour C; Lamy T; Lejeune F; Simon M; Traullé C; Vigier M; Maisonneuve H; Briére J; Colonna P; Andrieu JM
Cancer; 2002 Nov; 95(10):2169-79. PubMed ID: 12412171
[TBL] [Abstract][Full Text] [Related]
19. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K; Breuer K; Reineke T; May M; Nogova L; Klimm B; Schmitz T; Wildt L; Diehl V; Engert A;
J Clin Oncol; 2005 Oct; 23(30):7555-64. PubMed ID: 16234521
[TBL] [Abstract][Full Text] [Related]
20. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial.
Engert A; Franklin J; Eich HT; Brillant C; Sehlen S; Cartoni C; Herrmann R; Pfreundschuh M; Sieber M; Tesch H; Franke A; Koch P; de Wit M; Paulus U; Hasenclever D; Loeffler M; Müller RP; Müller-Hermelink HK; Dühmke E; Diehl V
J Clin Oncol; 2007 Aug; 25(23):3495-502. PubMed ID: 17606976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
